| dc.contributor.author | Imm, J | |
| dc.contributor.author | Kerrigan, TL | |
| dc.contributor.author | Jeffries, A | |
| dc.contributor.author | Lunnon, K | |
| dc.date.accessioned | 2018-06-14T15:36:02Z | |
| dc.date.issued | 2017-10-03 | |
| dc.description.abstract | It is thought that both genetic and epigenetic variation play a role in Alzheimer's disease initiation and progression. With the advent of somatic cell reprogramming into induced pluripotent stem cells it is now possible to generate patient-derived cells that are able to more accurately model and recapitulate disease. Furthermore, by combining this with recent advances in (epi)genome editing technologies, it is possible to begin to examine the functional consequence of previously nominated genetic variants and infer epigenetic causality from recently identified epigenetic variants. In this review, we explore the role of genetic and epigenetic variation in Alzheimer's disease and how the functional relevance of nominated loci can be investigated using induced pluripotent stem cells and (epi)genome editing techniques. | en_GB |
| dc.description.sponsorship | This work was funded by an Alzheimer’s Society project grant to KL (grant number AS-PG-2 14-038), an Alzheimer’s Research UK network co-operation grant to KL (grant number ARUK-NCG2017A-5) and an Alzheimer’s Association new investigator research grant to KL (grant number NIRG-14-320878). JI is supported by the Alzheimer’s Society Doctoral Training Centre in Dementia Research at the University of Exeter (grant number AS-DTC-2014-030) and the Garfield Weston Foundation. | en_GB |
| dc.identifier.citation | Vol. 9(11), pp. 1455 - 1468 | en_GB |
| dc.identifier.doi | 10.2217/epi-2017-0076 | |
| dc.identifier.uri | http://hdl.handle.net/10871/33205 | |
| dc.language.iso | en | en_GB |
| dc.publisher | Future Medicine | en_GB |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/28969469 | en_GB |
| dc.rights.embargoreason | Under embargo until 03 October 2018 in compliance with publisher policy. | en_GB |
| dc.subject | Alzheimer's disease | en_GB |
| dc.subject | CRISPR-Cas9 | en_GB |
| dc.subject | DNA methylation | en_GB |
| dc.subject | Alzheimer Disease | en_GB |
| dc.subject | Epigenesis, Genetic | en_GB |
| dc.subject | Genetic Variation | en_GB |
| dc.subject | Humans | en_GB |
| dc.subject | Induced Pluripotent Stem Cells | en_GB |
| dc.title | Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease | en_GB |
| dc.type | Article | en_GB |
| dc.identifier.issn | 1750-1911 | |
| exeter.place-of-publication | England | en_GB |
| dc.description | This is the author accepted manuscript. The final version is available from the publisher via the DOI in this record | en_GB |
| dc.identifier.journal | Epigenomics | en_GB |
